Sleep Medications: Prescription and Over-the-Counter Overview

Sleep medications span a broad pharmacological spectrum — from federally scheduled controlled substances requiring a prescriber's authorization to antihistamine-based products available without a prescription on any pharmacy shelf. Understanding how these agents differ in mechanism, regulatory status, evidence base, and risk profile is essential for anyone navigating treatment options for conditions such as insomnia, circadian disruption, or sleep-maintenance difficulties. This page provides a structured reference covering definitions, drug classes, mechanistic principles, classification boundaries, and documented tradeoffs.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps (Non-Advisory)
• Reference Table or Matrix

Definition and Scope

Sleep medications — also termed hypnotics or sedative-hypnotics in clinical pharmacology — are substances administered with the primary or secondary purpose of initiating or maintaining sleep. The U.S. Food and Drug Administration (FDA) regulates both prescription and over-the-counter (OTC) sleep aids under distinct approval pathways: prescription hypnotics require a New Drug Application (NDA) demonstrating efficacy and safety through controlled trials, while OTC sleep aids must conform to the FDA's OTC Monograph system, which sets standardized active ingredient and dosage parameters.

The Drug Enforcement Administration (DEA) further stratifies prescription sleep medications through the Controlled Substances Act scheduling framework. Most benzodiazepines are classified Schedule IV, indicating accepted medical use alongside recognized potential for dependence. Non-benzodiazepine receptor agonists (the "Z-drugs") carry the same Schedule IV designation. Suvorexant and lemborexant, orexin receptor antagonists, are Schedule IV as well, while sodium oxybate (used in narcolepsy with cataplexy) is Schedule III/I depending on formulation context.

The scope of sleep pharmacotherapy extends beyond dedicated hypnotics. Antidepressants such as trazodone (prescribed off-label in the majority of its sleep-related use), antipsychotics such as quetiapine, and anticonvulsants such as gabapentin are prescribed off-label for sleep, though none carry an FDA-approved insomnia indication. The regulatory context for sleep medicine also intersects with state-level prescribing rules, pharmacy benefit structures, and, increasingly, direct-to-consumer telehealth platforms subject to DEA rules on controlled substance prescribing.

Core Mechanics or Structure

Sleep medications produce their effects by modulating one or more of the neurochemical systems that govern sleep-wake cycling. The principal target systems are:

GABA-A Receptor Potentiation
Benzodiazepines (e.g., temazepam, triazolam) and non-benzodiazepine Z-drugs (zolpidem, eszopiclone, zaleplon) bind to GABA-A receptor complexes, enhancing the inhibitory effect of gamma-aminobutyric acid (GABA). This reduces neuronal excitability across wake-promoting circuits. Benzodiazepines bind non-selectively across GABA-A subunit configurations (α1, α2, α3, α5), while Z-drugs have greater α1 selectivity, which is associated with sedation rather than anxiolysis or muscle relaxation, though this selectivity is not absolute.

Orexin Receptor Antagonism
Orexin (also called hypocretin) neuropeptides produced in the lateral hypothalamus maintain wakefulness. Dual orexin receptor antagonists (DORAs) — including suvorexant (FDA-approved 2014) and lemborexant (FDA-approved 2019) — block both OX1R and OX2R receptors, effectively withdrawing the wake-promoting signal rather than broadly suppressing CNS activity. This mechanism is considered more targeted than GABA-A potentiation.

Histamine H1 Receptor Antagonism
Both OTC antihistamine sleep aids (diphenhydramine, doxylamine) and the prescription antidepressant doxepin (at doses of 3–6 mg, FDA-approved for sleep maintenance) act primarily through H1 receptor blockade. Histamine is a major arousal-promoting neurotransmitter; blocking H1 receptors in the tuberomammillary nucleus of the hypothalamus reduces wakefulness drive.

Melatonin Receptor Agonism
Ramelteon (FDA-approved 2005) targets MT1 and MT2 melatonin receptors in the suprachiasmatic nucleus (SCN), the brain's primary circadian pacemaker. This mechanism modulates sleep-onset timing rather than broadly inducing sedation. Ramelteon is the only FDA-approved prescription hypnotic with no scheduled status under the DEA. Exogenous melatonin and sleep supplements are sold OTC and are regulated as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994, not as drugs.

Causal Relationships or Drivers

The clinical use of sleep medications is driven by documented failures in sleep initiation, sleep maintenance, or early-morning awakening that persist despite behavioral interventions. The American Academy of Sleep Medicine (AASM) clinical practice guidelines, last comprehensively updated in 2017 (published in the Journal of Clinical Sleep Medicine), identify specific pharmacological agents with evidence ratings for chronic insomnia disorder.

Chronic insomnia disorder, defined in the International Classification of Sleep Disorders, 3rd edition (ICSD-3), as sleep difficulty occurring at least 3 nights per week for at least 3 months causing daytime impairment, affects an estimated 10–15% of U.S. adults according to figures cited by the National Institute of Neurological Disorders and Stroke (NINDS).

Pharmacotherapy is also driven by comorbid conditions. Sleep apnea, restless legs syndrome, narcolepsy, and circadian rhythm sleep-wake disorders each carry condition-specific pharmacological treatments distinct from general hypnotics. Iron supplementation and dopaminergic agents (pramipexole, ropinirole) address RLS through dopamine pathway modulation. Sodium oxybate and wake-promoting agents (modafinil, armodafinil, pitolisant, solriamfetol) treat narcolepsy through entirely different mechanisms.

The broader landscape of sleep research and current science continues to refine understanding of which populations respond to specific agents and which carry elevated risk for adverse outcomes.

Classification Boundaries

Sleep medications are most usefully classified along two independent axes: regulatory access (prescription vs. OTC vs. dietary supplement) and primary pharmacological mechanism.

Prescription-Only
- Benzodiazepines: temazepam, triazolam, flurazepam, quazepam (Schedule IV)
- Non-benzodiazepine Z-drugs: zolpidem, eszopiclone, zaleplon (Schedule IV)
- Orexin antagonists: suvorexant, lemborexant (Schedule IV)
- Melatonin receptor agonist: ramelteon (unscheduled)
- Low-dose doxepin: 3 mg and 6 mg formulations (unscheduled)

Over-the-Counter
- Diphenhydramine (e.g., Benadryl, ZzzQuil, Unisom SleepTabs in diphenhydramine formulation)
- Doxylamine succinate (e.g., Unisom SleepTabs in doxylamine formulation)
- Combination products (diphenhydramine + analgesics such as acetaminophen)

Dietary Supplement (DSHEA-regulated, not FDA drug-approved)
- Melatonin (sold in doses ranging from 0.5 mg to 10 mg OTC, though circadian-effective doses in research settings are typically 0.5–1 mg)
- Valerian root, L-theanine, magnesium glycinate — sold as supplements with no FDA-approved sleep indication

The classification boundary between OTC drugs and dietary supplements is regulatory, not pharmacological. An OTC drug must conform to FDA monograph standards or receive NDA approval; a dietary supplement may not claim to treat a disease and is not required to demonstrate efficacy before sale.

Tradeoffs and Tensions

Tolerance and Dependence
Benzodiazepines and Z-drugs produce physiological tolerance with regular use. The FDA mandated Boxed Warnings for all Z-drugs in 2019, citing risks including complex sleep behaviors (sleepwalking, sleep-driving) and dependency. The tension between short-term efficacy and long-term risk is central to clinical guideline development. The AASM's 2017 guidelines recommend most pharmacological agents only for short-term use while simultaneously acknowledging that chronic insomnia often persists long-term.

Off-Label Prescribing Volume
Trazodone is prescribed for sleep far more frequently than any FDA-approved hypnotic, despite carrying no sleep indication. This reflects real-world prescribing patterns that diverge substantially from approved labeling — a persistent tension in sleep pharmacology between what is evidence-approved and what is clinically common.

OTC Antihistamine Tolerance
Diphenhydramine produces rapid tolerance (within 3–4 consecutive nights, based on pharmacological literature), meaning repeat users may derive diminishing benefit while residual sedation ("hangover effect") the following day persists. For sleep in older adults, anticholinergic effects of antihistamines — including confusion, urinary retention, and dry mouth — represent a documented safety concern flagged by the American Geriatrics Society Beers Criteria.

Supplement Regulation Gap
Melatonin products sold as dietary supplements are not subject to pre-market efficacy testing. A 2017 analysis published in the Journal of Sleep Research (Erland & Saxena) tested 31 melatonin supplements and found that actual melatonin content ranged from 83% below to 478% above the labeled dose, with lot-to-lot variability within the same product brand. This regulatory gap — governed by DSHEA rather than FDA drug standards — creates a structural quality-control problem absent from prescription medications.

CBT-I as Comparative Standard
The AASM guidelines and the American College of Physicians (ACP) both position Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment for chronic insomnia disorder, with pharmacotherapy considered adjunctive or second-line. This creates a tension when access to trained CBT-I providers is limited — a structural reality across much of rural and underserved U.S. geography.

Common Misconceptions

"OTC means safe for long-term use."
FDA OTC drug monograph status means a substance is safe and effective when used as directed — which for sleep antihistamines explicitly means short-term (typically 2 weeks or fewer). The monograph does not authorize long-term nightly use. Chronic use of diphenhydramine has been investigated in relation to cognitive outcomes in older populations, with observational studies (including the ARIC cohort) noting associations, though causation is not established.

"Melatonin supplements are regulated like drugs."
Melatonin sold OTC in the United States is a dietary supplement under DSHEA, not an FDA-approved drug. Unlike in the European Union and the United Kingdom, where melatonin above low thresholds requires a prescription, the U.S. market has no dose ceiling or pre-market approval requirement for melatonin supplements.

"Z-drugs are non-addictive because they are 'non-benzodiazepines.'"
The "non-benzodiazepine" label refers to chemical structure, not mechanism or addiction profile. Z-drugs act on the same GABA-A receptor subtypes and carry Schedule IV controlled substance status precisely because the DEA recognizes their dependence potential. The FDA's 2019 Boxed Warning revision explicitly addressed this misconception in its public communications.

"Prescription hypnotics improve sleep architecture."
Benzodiazepines and Z-drugs generally suppress slow-wave sleep (N3) and can reduce REM sleep, altering rather than restoring normal sleep architecture. The subjective sense of sleeping better may not correspond to improvement in polysomnographically measured sleep stages.

"Higher melatonin doses work better."
Chronobiological research, including work from the Brigham and Women's Hospital circadian division, suggests that very low doses (0.5 mg) can be as effective as higher doses (5–10 mg) for circadian phase-shifting purposes, and that supraphysiologic doses may not further advance sleep onset while increasing daytime grogginess.

Checklist or Steps (Non-Advisory)

The following checklist describes the information elements typically involved in evaluating sleep medication options — presented as an informational framework, not clinical guidance:

Information Elements in Sleep Medication Evaluation

• [ ] Documented sleep complaint type identified: sleep-onset difficulty, sleep maintenance difficulty, early awakening, or mixed presentation
• [ ] Duration of sleep complaint established: acute (<1 month), subacute (1–3 months), or chronic (>3 months per ICSD-3 criteria)
• [ ] Comorbid sleep disorders screened: sleep apnea (via home sleep testing or polysomnography), RLS, PLMD, parasomnias
• [ ] Behavioral and non-pharmacological interventions documented as attempted or contraindicated
• [ ] Current medication list reviewed for pharmacological interactions and sedative-additive effects
• [ ] Substance use history reviewed (alcohol, cannabis, caffeine, stimulants)
• [ ] Age and comorbidity profile noted (geriatric considerations per Beers Criteria; pregnancy status per FDA labeling categories)
• [ ] DEA schedule and prescription status of target agent confirmed
• [ ] FDA-approved indication vs. off-label use status of target agent clarified
• [ ] Planned duration and discontinuation strategy identified for scheduled substances

The National Sleep Foundation and AASM both publish patient-facing resources aligned with these evaluation dimensions.

Reference Table or Matrix

Sleep Medication Class Comparison

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)